Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 BioPharmaceutical

Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Plus News From Resverlogix, Sun And Syntekabio

Executive Summary

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

You may also be interested in...



Coronavirus Update: Lilly Initiates 2,400-Patient Nursing Home Trial

Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.

Lilly May Face Q2 Blues As Prior Stocking Takes Effect

Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.

Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds

Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip
Scrip
Scrip
Pink Sheet
Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 BioPharmaceutical
Latest Headlines

China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public

Quick Listen: Scrip's Five Must-Know Things

AbbVie Exits CAR-T Cell Therapy Development Partnership With Caribou

Blueprint’s Evolution On Its Path To Financial Sustainability

See All
UsernamePublicRestriction

Register

SC142331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By